Interpace Biosciences Inc EV/EBIT
Cos'è EV/EBIT di Interpace Biosciences Inc?
EV/EBIT di Interpace Biosciences Inc è 1.01
Qual è la definizione di EV/EBIT?
Enterprise value to earnings before interest and taxes (EV/EBIT) is a financial ratio used to measure if a stock is priced appropriately to similar stocks and the market. It is similar to the P/E ratio.
ttm (trailing twelve months)
The EV/EBIT ratio addresses some of the shortcomings of the P/E ratio. Instead of taking market capitalization, the ratio uses enterprise value, as it takes into account the true value of the company. Enterprise value includes both equity and debt. It is calculated as:
Enterprise value = market cap + total debt – cash and cash equivalents
The EV/EBIT ratio is useful in comparing peers within the wider market. A high EV/EBIT ratio indicates that a company’s stock is overvalued. On the opposite, a low EV/EBIT ratio indicates that a company’s stock is undervalued. The lower the ratio, the more financially stable a company should be. However, investors and analyst should use other ratios and information to get a full picture of a company’s financial state and actual value.
EV/EBIT di aziende nel Health Care settore su NASDAQ rispetto a Interpace Biosciences Inc
Cosa fa Interpace Biosciences Inc?
advancing patient care through molecular diagnostic testing. interpace diagnostics develops molecular diagnostic tests. our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. you can be assured that all of the molecular tests we offer are driven by rigorous, validated science. we power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. the unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.
Aziende con ev/ebit simili a Interpace Biosciences Inc
- Recylex S.A ha EV/EBIT di 0.99
- Imunon Inc ha EV/EBIT di 1.00
- STM Plc ha EV/EBIT di 1.00
- A.P. Moller - Marsk A/S ha EV/EBIT di 1.00
- SandRidge Permian Trust ha EV/EBIT di 1.00
- Inozyme Pharma ha EV/EBIT di 1.01
- Interpace Biosciences Inc ha EV/EBIT di 1.01
- Ekotechnika Ag A O.N ha EV/EBIT di 1.02
- Cato ha EV/EBIT di 1.02
- Phio Pharmaceuticals ha EV/EBIT di 1.05
- United Oil & Gas Plc ha EV/EBIT di 1.05
- Virnetx Corp ha EV/EBIT di 1.07
- InMed Pharmaceuticals ha EV/EBIT di 1.07